|Title:||A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary, and Fallopian Tube Cancer. NCI-Supplied Agent: Bevacizumb (NSC #704865, IND #113912)|
|Study Description:||The main goal of this clinical research study is to learn if a second surgery |
to remove tumor tissue, followed by chemotherapy, can help patients to stay
Another purpose of this study is to test samples of your blood and, if you are
receiving surgery as part of this study, some of your primary tumor (if
available from a previous surgery or biopsy) and some of your recurrent tumor
and normal tissue (if available from the surgery done as part of this study).
The purpose of this research is to determine if this testing can be used in the
future to determine which patients may respond to treatment, have side effects,
or have a good prognosis.
Researchers would also like to compare the combination of carboplatin,
paclitaxel, and bevacizumab to the standard combination of carboplatin and
paclitaxel alone or carboplatin and gemcitabine alone, in treating ovarian,
primary peritoneal, or Fallopian tube cancer.